Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers
- PMID: 19675283
- DOI: 10.1152/ajpregu.00414.2009
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers
Abstract
The opioid growth factor (OGF) regulates cell proliferation of human cancer cells through the cyclin-dependent kinase inhibitory pathway, with mediation of this action by the OGF receptor (OGFr). The ubiquity of the OGF-OGFr axis in human cancer is unknown. We used 31 human cancer cell lines, representative of more than 90% of neoplasias occurring in humans, and found that OGF and OGFr were detected in the cytoplasm and nucleus by immunohistochemistry. The addition of OGF to cultures depressed cell number up to 41%, whereas naltrexone (NTX) increased cell proliferation by up to 44%, a total of 85% in the modulating capacity for the OGF-OGFr axis. Neutralization of OGF by specific antibodies led to a marked increase in cell number. Knockdown of OGFr by OGFr-siRNA resulted in a significant increase in the number of cells, even in the face of the addition of exogenous OGF. The cultures to which NTX was added and subjected to OGFr-siRNA were similar to those with OGF-siRNA alone. The OGF-OGFr axis, a physiological determinant of cell-proliferative activity, is a ubiquitous feature of human cancer cells. The identification of this native biological system in neoplasia may be important in understanding the pathophysiology of neoplasia, and in designing treatment modalities that utilize the body's own chemistry.
Similar articles
-
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1716-25. doi: 10.1152/ajpregu.00075.2009. Epub 2009 Mar 18. Am J Physiol Regul Integr Comp Physiol. 2009. PMID: 19297547
-
Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369. BMC Cancer. 2009. PMID: 19835629 Free PMC article.
-
T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.Immunobiology. 2011 May;216(5):579-90. doi: 10.1016/j.imbio.2010.09.014. Epub 2010 Sep 29. Immunobiology. 2011. PMID: 20965606
-
Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.Int Immunopharmacol. 2019 Oct;75:105723. doi: 10.1016/j.intimp.2019.105723. Epub 2019 Aug 9. Int Immunopharmacol. 2019. PMID: 31408839 Review.
-
Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.Int Immunopharmacol. 2019 Oct;75:105785. doi: 10.1016/j.intimp.2019.105785. Epub 2019 Aug 9. Int Immunopharmacol. 2019. PMID: 31404891 Review.
Cited by
-
Loss-of-function OGFRL1 variants identified in autosomal recessive cherubism families.JBMR Plus. 2024 Apr 9;8(6):ziae050. doi: 10.1093/jbmrpl/ziae050. eCollection 2024 Jun. JBMR Plus. 2024. PMID: 38699440 Free PMC article.
-
Involvement of the Opioid Peptide Family in Cancer Progression.Biomedicines. 2023 Jul 14;11(7):1993. doi: 10.3390/biomedicines11071993. Biomedicines. 2023. PMID: 37509632 Free PMC article. Review.
-
Systemic immune effects of anesthetics and their intracellular targets in tumors.Front Med (Lausanne). 2022 Jul 28;9:810189. doi: 10.3389/fmed.2022.810189. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35966857 Free PMC article. Review.
-
Antimicrobial Peptides and Cationic Nanoparticles: A Broad-Spectrum Weapon to Fight Multi-Drug Resistance Not Only in Bacteria.Int J Mol Sci. 2022 May 29;23(11):6108. doi: 10.3390/ijms23116108. Int J Mol Sci. 2022. PMID: 35682787 Free PMC article. Review.
-
Optimization of Influential Variables in the Development of Buprenorphine and Bupivacaine Loaded Invasome for Dermal Delivery.Adv Pharm Bull. 2021 May;11(3):522-529. doi: 10.34172/apb.2021.060. Epub 2020 Sep 19. Adv Pharm Bull. 2021. PMID: 34513627 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
